Relevant bibliographies by topics / Atopic dermatitis Treatment Malaysia / Journal articles

Journal articles on the topic 'Atopic dermatitis Treatment Malaysia'

To see the other types of publications on this topic, follow the link: Atopic dermatitis Treatment Malaysia.
Author: Grafiati
Published: 10 December 2022
Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Atopic dermatitis Treatment Malaysia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kim, Hei Sung, and Sang Hyun Cho. "Treatment for atopic dermatitis." Journal of the Korean Medical Association 57, no. 3 (2014): 226. http://dx.doi.org/10.5124/jkma.2014.57.3.226.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ha, Seog Jun, and Jin Wou Kim. "Treatment of Atopic Dermatitis." Journal of the Korean Medical Association 43, no. 10 (2000): 1013. http://dx.doi.org/10.5124/jkma.2000.43.10.1013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Krafchik, Bernice R. "Treatment of Atopic Dermatitis." Journal of Cutaneous Medicine and Surgery 3, no. 2_suppl (February 1999): S2–16—S2–23. http://dx.doi.org/10.1177/12034754990030s204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wergowske, Gilbert L. "Treatment-Resistant Atopic Dermatitis." Journal of the American Geriatrics Society 49, no. 7 (July 2001): 1008–9. http://dx.doi.org/10.1046/j.1532-5415.2001.49200.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Engler, D., F. Makola, and N. M. Magongwa. "Atopic Dermatitis." South African Family Practice 60, no. 6 (November 30, 2018): 26–33. http://dx.doi.org/10.4102/safp.v60i6.4932.

Full text
Abstract:
The aetiology of atopic dermatitis is multi-faceted and affects our first line host defence, the skin. Atopic dermatitis has a significant influence on a patient’s social and occupational functioning and can have long-lasting effects. The signs and symptoms of AD includes pruritus, erythema, fissuring, and lichenification – these are reduced by the use of moisturizing agents. Guidelines on how to manage atopic dermatitis aims to improve symptoms and achieve long-term disease control. Patient education remains as important as other treatment strategies and the pharmacist plays an integral role in educating patients on the management of their condition and adherence to therapy.
APA, Harvard, Vancouver, ISO, and other styles
6

Bata-Csörgő, Zsuzsanna. "Systemic treatment of atopic dermatitis." Bőrgyógyászati és Venerológiai Szemle 93, no. 5 (October 20, 2017): 240–42. http://dx.doi.org/10.7188/bvsz.2017.93.5.8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Thestrup-Pedersen, K. "Treatment principles of atopic dermatitis." Journal of the European Academy of Dermatology and Venereology 16, no. 1 (January 2002): 1–9. http://dx.doi.org/10.1046/j.1468-3083.2002.00349.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hsu, Chih-Jung, and Li-Fang Wang. "Emerging Treatment of Atopic Dermatitis." Clinical Reviews in Allergy & Immunology 33, no. 3 (July 13, 2007): 199–203. http://dx.doi.org/10.1007/s12016-007-0043-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Boguniewicz, Mark. "Topical treatment of atopic dermatitis." Immunology and Allergy Clinics of North America 24, no. 4 (November 2004): 631–44. http://dx.doi.org/10.1016/j.iac.2004.06.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Esteve-Martínez, A., A. García-Rabasco, J. Miralles, and J. de-la-Cuadra-Oyanguren. "Treatment-Resistant Adult Atopic Dermatitis." Actas Dermo-Sifiliográficas (English Edition) 102, no. 10 (December 2011): 821–22. http://dx.doi.org/10.1016/j.adengl.2012.01.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Chovatiya, Raj. "Atopic Dermatitis (Eczema)." JAMA 329, no. 3 (January 17, 2023): 268. http://dx.doi.org/10.1001/jama.2022.21457.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Thomsen, Simon Francis. "Atopic Dermatitis: Natural History, Diagnosis, and Treatment." ISRN Allergy 2014 (April 2, 2014): 1–7. http://dx.doi.org/10.1155/2014/354250.

Full text
Abstract:
Atopic dermatitis is an inflammatory skin disease with early onset and with a lifetime prevalence of approximately 20%. The aetiology of atopic dermatitis is unknown, but the recent discovery of filaggrin mutations holds promise that the progression of atopic dermatitis to asthma in later childhood may be halted. Atopic dermatitis is not always easily manageable and every physician should be familiar with the fundamental aspects of treatment. This paper gives an overview of the natural history, clinical features, and treatment of atopic dermatitis.
APA, Harvard, Vancouver, ISO, and other styles
13

Werfel, Thomas, Annice Heratizadeh, Werner Aberer, Frank Ahrens, Matthias Augustin, Tilo Biedermann, Thomas Diepgen, et al. "Update “Systemic treatment of atopic dermatitis” of the S2k‐guideline on atopic dermatitis." JDDG: Journal der Deutschen Dermatologischen Gesellschaft 19, no. 1 (January 2021): 151–68. http://dx.doi.org/10.1111/ddg.14371.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Murakami, Yoko. "Treatment of childhood intractable atopic dermatitis." Nihon Shoni Arerugi Gakkaishi. The Japanese Journal of Pediatric Allergy and Clinical Immunology 34, no. 5 (December 20, 2020): 584–93. http://dx.doi.org/10.3388/jspaci.34.584.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Cookson, Hannah, and Catherine Smith. "Systemic treatment of adult atopic dermatitis." Clinical Medicine 12, no. 2 (April 2012): 172–76. http://dx.doi.org/10.7861/clinmedicine.12-2-172.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Kubanova, A. A., A. A. Kubanov, A. E. Karamova, and D. V. Proshutinskaya. "Biological Therapeutic Treatment of Atopic Dermatitis." Vestnik dermatologii i venerologii, no. 5 (January 1, 2017): 34–46. http://dx.doi.org/10.25208/0042-4609-2017-93-5-34-46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Kawashima, Makoto. "Pathogenesis and treatment of atopic dermatitis." Japanese Journal of Clinical Immunology 22, no. 6 (1999): 382–85. http://dx.doi.org/10.2177/jsci.22.382.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Macharadze, D. Sh. "ATOPIC DERMATITIS: NEW ASPECTS OF TREATMENT." Current pediatrics 12, no. 5 (September 19, 2013): 80. http://dx.doi.org/10.15690/vsp.v12i5.802.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Park, Chun Wook. "The Pharmacologic Treatment of Atopic Dermatitis." Journal of the Korean Medical Association 49, no. 11 (2006): 1046. http://dx.doi.org/10.5124/jkma.2006.49.11.1046.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

EGUTI, Kazuko, Takefumi OKADA, Masanori TAKASHI, Setsuo SANO, and Atsunobu SINDOU. "Acupuncture Treatment of Intractable Atopic Dermatitis." Zen Nihon Shinkyu Gakkai zasshi (Journal of the Japan Society of Acupuncture and Moxibustion) 45, no. 4 (1995): 253–57. http://dx.doi.org/10.3777/jjsam.45.253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

ARCHER, C. B., and D. M. MACDONALD. "Treatment of atopic dermatitis with salbutamol." Clinical and Experimental Dermatology 12, no. 5 (September 1987): 323–25. http://dx.doi.org/10.1111/j.1365-2230.1987.tb02500.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Zainullina, O. N., Z. R. Khismatullina, and D. V. Pechkurov. "Glucocorticoid-resistant atopic dermatitis: treatment options." Voprosy praktičeskoj pediatrii 15, no. 3 (2020): 87–89. http://dx.doi.org/10.20953/1817-7646-2020-3-87-89.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Uysal, Pinar, and Nevin Uzuner. "Treatment of atopic dermatitis in children." Journal of Dr. Behcet Uz Children's Hospital 3, no. 2 (July 31, 2013): 77–86. http://dx.doi.org/10.5222/buchd.2013.077.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Seegräber, Marlene, Jerome Srour, Alexandra Walter, Macarena Knop, and Andreas Wollenberg. "Dupilumab for treatment of atopic dermatitis." Expert Review of Clinical Pharmacology 11, no. 5 (March 20, 2018): 467–74. http://dx.doi.org/10.1080/17512433.2018.1449642.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Babalola, Olubukola, and Bruce E. Strober. "Treatment of atopic dermatitis in pregnancy." Dermatologic Therapy 26, no. 4 (July 2013): 293–301. http://dx.doi.org/10.1111/dth.12074.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Marks, Ronald. "Systemic treatment for severe atopic dermatitis." Journal of Dermatological Treatment 7, sup3 (January 1996): S13—S15. http://dx.doi.org/10.3109/09546639609097189.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Dohil, Magdalene A., and Lawrence F. Eichenfield. "A Treatment Approach for Atopic Dermatitis." Pediatric Annals 34, no. 3 (March 1, 2005): 201–10. http://dx.doi.org/10.3928/0090-4481-20050301-09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Spergel, Jonathan M. "Immunology and Treatment of Atopic Dermatitis." American Journal of Clinical Dermatology 9, no. 4 (2008): 233–44. http://dx.doi.org/10.2165/00128071-200809040-00003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

LINTU, P. "Peroral ketokonazole treatment of atopic dermatitis." Journal of the European Academy of Dermatology and Venereology 11 (September 1998): S134. http://dx.doi.org/10.1016/s0926-9959(98)95041-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Baron, Elma D., and Seth R. Stevens. "Light treatment modalities for atopic dermatitis." Immunology and Allergy Clinics of North America 22, no. 1 (February 2002): 125–40. http://dx.doi.org/10.1016/s0889-8561(03)00073-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

SPORIK, R., and A. KEMP. "Topical triclosan treatment of atopic dermatitis." Journal of Allergy and Clinical Immunology 99, no. 6 (June 1997): 861. http://dx.doi.org/10.1016/s0091-6749(97)80029-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Kawana, Seiji. "Diagnosis and treatment of Atopic dermatitis." Nippon Ika Daigaku Zasshi 66, no. 4 (1999): 279–82. http://dx.doi.org/10.1272/jnms.66.279.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Huang, Amy, Christine Cho, Donald Y. M. Leung, and Kanwaljit Brar. "Atopic Dermatitis: Early Treatment in Children." Current Treatment Options in Allergy 4, no. 3 (August 1, 2017): 355–69. http://dx.doi.org/10.1007/s40521-017-0140-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

van der Schaft, Jorien, Judith L. Thijs, Floor M. Garritsen, D. Balak, and Marjolein S. de Bruin-Weller. "Towards personalized treatment in atopic dermatitis." Expert Opinion on Biological Therapy 19, no. 5 (February 26, 2019): 469–76. http://dx.doi.org/10.1080/14712598.2019.1583204.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Giavina-Bianchi, Mara, and Pedro Giavina-Bianchi. "Systemic Treatment for Severe Atopic Dermatitis." Archivum Immunologiae et Therapiae Experimentalis 67, no. 2 (August 22, 2018): 69–78. http://dx.doi.org/10.1007/s00005-018-0521-y.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Prezzano, James C., and Lisa A. Beck. "Long-Term Treatment of Atopic Dermatitis." Dermatologic Clinics 35, no. 3 (July 2017): 335–49. http://dx.doi.org/10.1016/j.det.2017.02.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

KOUTINAS (Α.Φ. ΚΟΥΤΙΝΑΣ), A. F., and M. N. SARIDOMICHELAKIS (Μ.Ν. ΣΑΡΙΔΟΜΙΧΕΛΑΚΗΣ). "Feline atopic dermatitis." Journal of the Hellenic Veterinary Medical Society 48, no. 1 (January 31, 2018): 17. http://dx.doi.org/10.12681/jhvms.15789.

Full text
Abstract:
Atopy is a highly pruritic skin disease in cats that have positive intradermal test reactions mostly to non - seasonal allergens (house dust mites). It's pathogenesis is unknown, though it is believed that a reaginic antibody exists resemblin IgE. Young cats appear to be predisposed. The most consistent feature of the disease is pruritus, heralding its clinical picture. The four most commonly occurring cutaneous reaction patterns are military dermatitis, eosinophilic granuloma complex lesions, selfinduced alopecia or hypotrichosis and lesionai or nonlesional pruritus of the face, neck and pinnae. The definitive diagnosis of feline atopy requires a positive intradermal allergy test reaction, good flea control, a poor response to a 9 to 13 -week course of a hypoallergenic diet and negative fungal cultures plus skin scrapings for pathogenic mites. The treatment plan may include avoidance of allergens, glucocortidoids (repositol methylprednisolon, dexamethason), ω/3 - ω/6 fatty acid supplements, antihistamines (chlopheniramine, clemastine) and/or mast cell stabilizers (oxatomide) and hyposensitization.
APA, Harvard, Vancouver, ISO, and other styles
38

إسماعيل, Kenan Omar, Basel Mahmoud أيوب, and Asem Mohammad Khader البواب. "A Child Girl Has Severe Case of Pediatric Atopic Dermatitis: Treatment with Terbinafine Hydrochloride." Journal of medical and pharmaceutical sciences 6, no. 4 (September 25, 2022): 84–88. http://dx.doi.org/10.26389/ajsrp.s031221.

Full text
Abstract:
Atopic dermatitis in early childhood accounts for 20% of all atopic dermatitis occurrences, with similar atopic dermatitis symptomology of red pustules or scales characteristic. The potential causation of atopic dermatitis varies, may be hereditary in some cases. Combination topical therapies are used to treat patients with a compromised skin barrier. There are few safe and regulated pharmacotherapeutic atopic dermatitis therapies for pediatric use, and current treatment satisfaction is low. Here we provide details of the successful treatment of a pediatric patient with pustular atopic dermatitis using topical application of terbinafine hydrochloride in tandem with maternal diet control on July 22, 2020 at AYA Medical Center in Sydney, Australia. After a six-month follow-up, the patient's symptoms had fully recovered. Thus, Terbinafine hydrochloride may be useful in the treatment of atopic dermatitis in children.
APA, Harvard, Vancouver, ISO, and other styles
39

Torres, Tiago, Eduarda Osório Ferreira, Margarida Gonçalo, Pedro Mendes-Bastos, Manuela Selores, and Paulo Filipe. "Update on Atopic Dermatitis." Acta Médica Portuguesa 32, no. 9 (September 2, 2019): 606. http://dx.doi.org/10.20344/amp.11963.

Full text
Abstract:
With an increasing prevalence during the past decades, atopic dermatitis has become a global health issue. A literature search following a targeted approach was undertaken to perform this non-systematic review, which intends to provide an overview of the epidemiology, pathophysiology, clinical features, comorbidities, and current therapies for the treatment of atopic dermatitis. In sum, this is a heterogeneous skin disorder associated with variable morphology, distribution, and disease course. Although not completely understood, its pathogenesis is complex and seems to result from a combination of genetic and environmental factors that induce skin barrier dysfunction, cutaneous and systemic immune dysregulation, skin microbiota dysbiosis, and a strong genetic influence. Diagnosis is based on specific criteria that consider patient and family history and clinical manifestations. Overall disease severity must be determined by evaluating both objective signs and subjective symptoms. Therapeutic goals require a multistep approach, focusing on reducing pruritus and establishing disease control. Patients should be advised on basic skin care and avoidance of triggers. Topical anti-inflammatory agents should be considered in disease flares or chronic/recurrent lesions. In case of inadequate response, phototherapy, systemic immunosuppressants and, more recently, dupilumab, should be added. Nevertheless, the treatment of moderate-to-severe atopic dermatitis remains challenging and novel, efficacious, safe and targeted treatments are urgently needed. In conclusion, although the last few years have seen important improvement in the understanding of the disease, future research in atopic dermatitis will continue exploring gene-environment interactions and how it affects pathophysiology, disease severity, and treatment outcomes.
APA, Harvard, Vancouver, ISO, and other styles
40

Lipscomb, Hannah, and Filippo De Bellis. "Management of canine atopic dermatitis." Companion Animal 25, no. 6 (July 2, 2020): 162–67. http://dx.doi.org/10.12968/coan.2020.0007.

Full text
Abstract:
Canine atopic dermatitis can present in two different ways — acute versus chronic — which require different treatment. When dealing with an acute flare, it is important to try and identify and eliminate the trigger and then provide fast-acting topical and/or systemic treatment. The treatment of chronic atopic dermatitis differs as it includes identification of flare factors, treatment of pruritus and prevention strategies. For long-term treatment of pruritus, there are currently four licenced prescription options available: oral glucocorticoids, oral ciclosporin, oral oclacitinib and injectable lokivetmab. The key prevention strategy for canine atopic dermatitis is allergen-specific immunotherapy and it is currently the only treatment that may induce complete remission of clinical signs. Alongside treatment for cases of canine atopic dermatitis, it is important to effectively communicate with clients in order to achieve compliance and medical adherence.
APA, Harvard, Vancouver, ISO, and other styles
41

Cline, Abigail, Gregory J. Bartos, Lindsay C. Strowd, and Steven R. Feldman. "Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis." Children 6, no. 9 (September 11, 2019): 103. http://dx.doi.org/10.3390/children6090103.

Full text
Abstract:
Background and Objectives: Severe, recalcitrant cases of pediatric psoriasis or atopic dermatitis may necessitate treatment with biological agents; however, this may be difficult due to lack of treatment options and standardized treatment guidelines. This review evaluates the biological treatment options available, including off-label uses, and provides a basic therapeutic guideline for pediatric psoriasis and atopic dermatitis. Materials and Methods: A PubMed review of biological treatments for pediatric psoriasis and atopic dermatitis with information regarding age, efficacy, dosing, contra-indications, adverse events, and off-label treatments. Results: Currently there are three European Medicines Agency (EMA)-approved biological treatment options for pediatric psoriasis: etanercept, ustekinumab, and adalimumab. While dupilumab was recently Food and Drug Administration (FDA)- and EMA-approved for adult atopic dermatitis, it is still not yet approved for pediatric atopic dermatitis. Conclusions: Given the high morbidity associated with pediatric atopic dermatitis and psoriasis, there is a need for more treatment options. Further research and post-marketing registries are needed to extend the use of biologics into pediatric patients.
APA, Harvard, Vancouver, ISO, and other styles
42

Fujimura, M., Y. Nakatsuji, and H. Ishimaru. "Cyclosporin A Treatment in Intrinsic Canine Atopic Dermatitis (Atopic-like Dermatitis): Open Trial Study." Polish Journal of Veterinary Sciences 19, no. 3 (September 1, 2016): 567–72. http://dx.doi.org/10.1515/pjvs-2016-0071.

Full text
Abstract:
Abstract In this study, dogs were separated into two groups and treated with immunosuppressant (Cyclosporin A: CsA). The first group was the canine atopic dermatitis (CAD) group, which is similar to extrinsic atopic dermatitis (AD) in humans (treated with a CsA dose of 2.5-5.5 mg/kg, n=8), and the second group was the canine atopic-like dermatitis (ALD) group, which is similar to intrinsic AD in humans (treated with a CsA dose of 2.5-6.5 mg/kg, n=14). The canine atopic dermatitis extent and severity index (CADESI)-4 was evaluated before treatment (PRE) and after treatment (POST) to assess the effectiveness of CsA for the two groups. In the CAD group, CADESI-4 showed no change (PRE:79±29, POST:77±28) and out of the eight dogs, no dogs showed complete remission, three dogs showed partial remission, and five dogs showed no effect. Whereas in the ALD group, CADESI-4 showed a significant reduction (PRE: 61±42, POST: 32±25, p<0.01) and out of the 14 dogs, 11 dogs showed complete remission, two dogs showed partial remission, and one dog showed no effect. The results indicate that the immunosuppressant showed effectiveness for the dogs diagnosed with ALD. One dog had to be treated for a year and eight months, which was the longest period in the study, this dog presented with hyperplasia of the lymphoidgland and mammary tumor.
APA, Harvard, Vancouver, ISO, and other styles
43

Dombrovskaya, Darya Konstantinovna, and Elina Vladimirovna Kravchenko. "Atopic dermatitis and pregnancy." Journal of obstetrics and women's diseases 61, no. 5 (September 15, 2012): 112–14. http://dx.doi.org/10.17816/jowd615112-114.

Full text
Abstract:
The article describes the features of the course of atopic dermatitis during pregnancy. The results of our investigation devoted to the state of the skin barrier in pregnant women with atopic dermatitis and healthy pregnant women are represented. We elucidate the advanced ideas of the feasibility of treatment atopic dermatitis during gestation
APA, Harvard, Vancouver, ISO, and other styles
44

Pescitelli, Leonardo, Elia Rosi, Federica Ricceri, Nicola Pimpinelli, and Francesca Prignano. "Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis." Current Pharmaceutical Biotechnology 22, no. 1 (December 31, 2020): 73–84. http://dx.doi.org/10.2174/1389201021666200611112755.

Full text
Abstract:
Background: Atopic Dermatitis is one of the most common inflammatory skin diseases, with an estimated prevalence of 2.1-4.9% in adults. Recently, advances in Atopic Dermatitis understanding have highlighted the role of inappropriate Th2 cell activation as principally involved in its pathogenesis. Other immune pathways seem to play a key role in the complex Atopic Dermatitis pathophysiology. The anti-IL-4/IL-13 was the first monoclonal antibody approved for the treatment of moderate to severe atopic dermatitis in adult patients whose disease is resistant to other therapies. Following its interesting results in terms of efficacy and safety, new therapies are in development. Methods: Monoclonal antibodies targeting IL-5, IL-13, IL-17, IL-22, IL-23, IL-31 and TSLP are currently under investigation on patients with moderate to severe Atopic Dermatitis patients. Moreover, small molecules like anti-PDE4 and JAK inhibitors may also represent other treatment possibilities. Results: In this section, we present data available on the efficacy and safety of newer molecules for the treatment of Atopic Dermatitis. Conclusion: The extreme clinical heterogeneity and the chronic progression of Atopic Dermatitis need for newer, safer and more effective treatments, able to control the disease and to improve the quality of life of affected patients. Dupilumab, and the other monoclonal antibodies and small molecules currently under investigation aim to improve the clinical management of Atopic Dermatitis.
APA, Harvard, Vancouver, ISO, and other styles
45

Faergemann, Jan. "Atopic Dermatitis and Fungi." Clinical Microbiology Reviews 15, no. 4 (October 2002): 545–63. http://dx.doi.org/10.1128/cmr.15.4.545-563.2002.

Full text
Abstract:
SUMMARY Atopic dermatitis (AD) is a chronic, itching, inflammatory skin disease which is associated with asthma and/or hay fever and a familial occurrence of these conditions. Genetic factors are important in the development of AD, but the exact hereditary pathway is still unknown. Dry skin and the weakened barrier function in patients with AD is very important for the patient's reactions to irritants and other external trigger factors including microorganisms. The standard treatments are topical corticosteroids, topical immunomodulating agents, and emollients. If AD cannot be controlled by this type of treatment, systemic immunomodulating agents may be used. UVB, UVA, or psoralen-UVA may also be used for widespread severe lesions. However, some patients do not respond to these standard treatment, and then it is important to consider the role of microorganisms, house dust mites or food. The role of the Malassezia yeasts in AD, especially AD located to the head and neck region, is now documented in several papers. There are also several papers indicating the role of Candida as an aggravating factor in AD. Patients with AD also develop chronic dermatophyte infections more easily, and patients with AD and chronic dermatophyte infections may show improvement in their AD when treated with antifungal drugs.
APA, Harvard, Vancouver, ISO, and other styles
46

Orlov, E. V., and P. E. Konnov. "The role of antihistamines in chronic actinic dermatitis treatment." Vestnik dermatologii i venerologii 92, no. 1 (February 24, 2016): 81–84. http://dx.doi.org/10.25208/0042-4609-2016-92-1-81-84.

Full text
Abstract:
Inveterate actinic dermatitis is an immunologically mediated photodermatosis characterized by itchy eczematous dermhelminthiasis exposed to sunlight. The disease proceeds in the same way as the atopic eczema or atopic dermatitis. The treatment of patients with inveterate actinic dermatitis is similar to the treatment of patients with atopic dermatitis and eczema. Administration of the modern antihistaminic preparation desloratadine (Aerius) in the treatment has a positive effect on the skin process relief and on some cellular and humoral immunity factors.
APA, Harvard, Vancouver, ISO, and other styles
47

Yudina, S. M., I. A. Ivanova, T. S. Rusanova, S. M. Yudina, I. A. Ivanova, and T. S. Rusanova. "Clinical effectiveness of efferent methods in complex treatment of atopic dermatitis." Russian Journal of Allergy 8, no. 4 (December 15, 2011): 34–39. http://dx.doi.org/10.36691/rja845.

Full text
Abstract:
Background. Clinical effectiveness estimation of efferent methods in complex treatment of Atopic Dermatitis. Method. the clinical effectiveness of intravenous laser blood radiation treatment (ivlBR), intravenous ultraviolet blood radiation treatment (ivUvBR) and extracorporal immunopharmacotherapy (eipt) was estimated in 198 patients with different clinical types of Atopic Dermatitis. Group of control included patients with standard basic therapy. Results. in patients with Atopic Dermatitis who had complex treatment ivlBR, ivUvBR, eipt was more rapid regression of inflammatory skin process and dynamic of index SCORAD were more rapid. this leaded to saving therapy time and reduction of relapses. Conclusion. the best effectiveness in treatment of Atopic Dermatitis complicated by secondary infection has ivUvBR or eipt with diuciphonum; in treatment of non-complicated of Atopic Dermatitis has ivlBR or eipt with dexametason.
APA, Harvard, Vancouver, ISO, and other styles
48

Elisyutina, O. G., E. S. Fedenko, and O. V. Shtirbul. "Sertaconazole in treatment of atopic dermatitis patients." Russian Journal of Allergy 10, no. 2 (December 15, 2013): 66–73. http://dx.doi.org/10.36691/rja647.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Ring, J., A. Alomar, T. Bieber, M. Deleuran, A. Fink-Wagner, C. Gelmetti, U. Gieler, et al. "Guidelines for treatment of atopic eczema (atopic dermatitis) Part I." Journal of the European Academy of Dermatology and Venereology 26, no. 8 (July 18, 2012): 1045–60. http://dx.doi.org/10.1111/j.1468-3083.2012.04635.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Ring, J., A. Alomar, T. Bieber, M. Deleuran, A. Fink-Wagner, C. Gelmetti, U. Gieler, et al. "Guidelines for treatment of atopic eczema (atopic dermatitis) Part II." Journal of the European Academy of Dermatology and Venereology 26, no. 9 (July 19, 2012): 1176–93. http://dx.doi.org/10.1111/j.1468-3083.2012.04636.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Atopic dermatitis Treatment Malaysia' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography